Antibody titers of individuals vaccinated for COVID-19: A systematic review
An important preventive measure to mitigate the COVID-19 pandemic is vaccine implementation. In creating vaccines, evoking neutralizing antibody (NAb) production is the main objective. This review determines and compares the NAb titers produced by COVID-19 vaccine recipients based on the vaccine typ...
Gespeichert in:
| Veröffentlicht in: | Journal of biosciences 2023-09, Vol.48 (3), p.32-32, Article 32 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 32 |
|---|---|
| container_issue | 3 |
| container_start_page | 32 |
| container_title | Journal of biosciences |
| container_volume | 48 |
| creator | Domado, Aminoddin M Adaza, Homobono Jacob F Beltran, Andrea Pauline Nicole C Buenviaje, Leila M Co, Catherine D Combalicer, Leira R Corona, Shiela May A Cruz, John Benedict F Dinjotian, Maria Adrianne Camille G Esperanzate, Eli Marie S Luna, Shaira Reinalyn G Pascua, Ethelbert Justine R Vicencio, Richard Rupert T Reyes, Sherwin N |
| description | An important preventive measure to mitigate the COVID-19 pandemic is vaccine implementation. In creating vaccines, evoking neutralizing antibody (NAb) production is the main objective. This review determines and compares the NAb titers produced by COVID-19 vaccine recipients based on the vaccine type and the manner of administration. This review includes published articles on studies with healthy participants with a minimum age of 18 years, without previous infections, and those who were given Emergency Use License (EUL) vaccines from WHO. Bias assessment was performed using the Cochrane Risk of Bias and the Newcastle–Ottawa Scale. In all the studies, 40.82% of the primary doses were viral vector platforms. For booster doses, 50% were mRNA platforms. Messenger RNA (mRNA) vaccines have higher titers as homologous than as heterologous vaccines. However, inactivated vaccines and viral vector vaccines have lower titers as homologous than as heterologous vaccines. Meanwhile, subunit vaccines lack data for their titers. Based on the antibody titers, homologous mRNA vaccines are more viral-protective than their heterologous counterparts. Heterologous inactivated and viral vector vaccines are more protective than homologous combinations, mainly when mRNA is the other type in those heterologous combinations. This is because mRNA vaccines elicit higher immunogenicity compared to other types. |
| doi_str_mv | 10.1007/s12038-023-00355-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3153200919</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2859992999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-a160e0411997686f472ccb3e01a24c7796f9355a3546e136fe1bfb506f06ad363</originalsourceid><addsrcrecordid>eNqFkc9Kw0AQh4MoWKsv4CngxUt0JpNsst5K_QuFXtTrstnsypY2qbtJpW_js_hkrkZQPOhhmDl8vx8MXxQdI5whQHHuMQUqE0gpAaA8T3AnGgEvKCmQyt0f93504P0CAHlGMIpmk6azVVtv48522vm4NbFtaruxdS-XPt5IpWwjO13HpnVvr9P5491lgvwinsR-6zu9kp1VsdMbq18Ooz0TQvroa4-jh-ur--ltMpvf3E0ns0QRsS6RyEBDhsh5wUpmsiJVqiINKNNMFQVnhocfJOUZ00jMaKxMlQMzwGRNjMbR6dC7du1zr30nVtYrvVzKRre9F4Q5pQAc-b9oWjJkWU5AAT35hS7a3jXhkUDlnPM0TKDSgVKu9d5pI9bOrqTbCgTx4UIMLkRwIT5dCAwhGkI-wM2Tdt_Vf6TeATXmifg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2859992999</pqid></control><display><type>article</type><title>Antibody titers of individuals vaccinated for COVID-19: A systematic review</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Indian Academy of Sciences</source><source>SpringerLink Journals - AutoHoldings</source><creator>Domado, Aminoddin M ; Adaza, Homobono Jacob F ; Beltran, Andrea Pauline Nicole C ; Buenviaje, Leila M ; Co, Catherine D ; Combalicer, Leira R ; Corona, Shiela May A ; Cruz, John Benedict F ; Dinjotian, Maria Adrianne Camille G ; Esperanzate, Eli Marie S ; Luna, Shaira Reinalyn G ; Pascua, Ethelbert Justine R ; Vicencio, Richard Rupert T ; Reyes, Sherwin N</creator><creatorcontrib>Domado, Aminoddin M ; Adaza, Homobono Jacob F ; Beltran, Andrea Pauline Nicole C ; Buenviaje, Leila M ; Co, Catherine D ; Combalicer, Leira R ; Corona, Shiela May A ; Cruz, John Benedict F ; Dinjotian, Maria Adrianne Camille G ; Esperanzate, Eli Marie S ; Luna, Shaira Reinalyn G ; Pascua, Ethelbert Justine R ; Vicencio, Richard Rupert T ; Reyes, Sherwin N</creatorcontrib><description>An important preventive measure to mitigate the COVID-19 pandemic is vaccine implementation. In creating vaccines, evoking neutralizing antibody (NAb) production is the main objective. This review determines and compares the NAb titers produced by COVID-19 vaccine recipients based on the vaccine type and the manner of administration. This review includes published articles on studies with healthy participants with a minimum age of 18 years, without previous infections, and those who were given Emergency Use License (EUL) vaccines from WHO. Bias assessment was performed using the Cochrane Risk of Bias and the Newcastle–Ottawa Scale. In all the studies, 40.82% of the primary doses were viral vector platforms. For booster doses, 50% were mRNA platforms. Messenger RNA (mRNA) vaccines have higher titers as homologous than as heterologous vaccines. However, inactivated vaccines and viral vector vaccines have lower titers as homologous than as heterologous vaccines. Meanwhile, subunit vaccines lack data for their titers. Based on the antibody titers, homologous mRNA vaccines are more viral-protective than their heterologous counterparts. Heterologous inactivated and viral vector vaccines are more protective than homologous combinations, mainly when mRNA is the other type in those heterologous combinations. This is because mRNA vaccines elicit higher immunogenicity compared to other types.</description><identifier>ISSN: 0973-7138</identifier><identifier>ISSN: 0250-5991</identifier><identifier>EISSN: 0973-7138</identifier><identifier>DOI: 10.1007/s12038-023-00355-1</identifier><language>eng</language><publisher>New Delhi: Springer India</publisher><subject>Antibodies ; Bias ; Biomedical and Life Sciences ; Biomedicine ; Cell Biology ; COVID-19 ; COVID-19 infection ; COVID-19 vaccines ; Deactivation ; Disease control ; Homology ; Immunogenicity ; Life Sciences ; messenger RNA ; Microbiology ; mRNA ; mRNA vaccines ; Pandemics ; Plant Sciences ; Platforms ; Review ; Reviews ; risk ; systematic review ; Vaccines ; Vectors (Biology) ; Work platforms ; Zoology</subject><ispartof>Journal of biosciences, 2023-09, Vol.48 (3), p.32-32, Article 32</ispartof><rights>Indian Academy of Sciences 2023</rights><rights>Indian Academy of Sciences 2023.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c336t-a160e0411997686f472ccb3e01a24c7796f9355a3546e136fe1bfb506f06ad363</cites><orcidid>0000-0002-0435-7731</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12038-023-00355-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12038-023-00355-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids></links><search><creatorcontrib>Domado, Aminoddin M</creatorcontrib><creatorcontrib>Adaza, Homobono Jacob F</creatorcontrib><creatorcontrib>Beltran, Andrea Pauline Nicole C</creatorcontrib><creatorcontrib>Buenviaje, Leila M</creatorcontrib><creatorcontrib>Co, Catherine D</creatorcontrib><creatorcontrib>Combalicer, Leira R</creatorcontrib><creatorcontrib>Corona, Shiela May A</creatorcontrib><creatorcontrib>Cruz, John Benedict F</creatorcontrib><creatorcontrib>Dinjotian, Maria Adrianne Camille G</creatorcontrib><creatorcontrib>Esperanzate, Eli Marie S</creatorcontrib><creatorcontrib>Luna, Shaira Reinalyn G</creatorcontrib><creatorcontrib>Pascua, Ethelbert Justine R</creatorcontrib><creatorcontrib>Vicencio, Richard Rupert T</creatorcontrib><creatorcontrib>Reyes, Sherwin N</creatorcontrib><title>Antibody titers of individuals vaccinated for COVID-19: A systematic review</title><title>Journal of biosciences</title><addtitle>J Biosci</addtitle><description>An important preventive measure to mitigate the COVID-19 pandemic is vaccine implementation. In creating vaccines, evoking neutralizing antibody (NAb) production is the main objective. This review determines and compares the NAb titers produced by COVID-19 vaccine recipients based on the vaccine type and the manner of administration. This review includes published articles on studies with healthy participants with a minimum age of 18 years, without previous infections, and those who were given Emergency Use License (EUL) vaccines from WHO. Bias assessment was performed using the Cochrane Risk of Bias and the Newcastle–Ottawa Scale. In all the studies, 40.82% of the primary doses were viral vector platforms. For booster doses, 50% were mRNA platforms. Messenger RNA (mRNA) vaccines have higher titers as homologous than as heterologous vaccines. However, inactivated vaccines and viral vector vaccines have lower titers as homologous than as heterologous vaccines. Meanwhile, subunit vaccines lack data for their titers. Based on the antibody titers, homologous mRNA vaccines are more viral-protective than their heterologous counterparts. Heterologous inactivated and viral vector vaccines are more protective than homologous combinations, mainly when mRNA is the other type in those heterologous combinations. This is because mRNA vaccines elicit higher immunogenicity compared to other types.</description><subject>Antibodies</subject><subject>Bias</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cell Biology</subject><subject>COVID-19</subject><subject>COVID-19 infection</subject><subject>COVID-19 vaccines</subject><subject>Deactivation</subject><subject>Disease control</subject><subject>Homology</subject><subject>Immunogenicity</subject><subject>Life Sciences</subject><subject>messenger RNA</subject><subject>Microbiology</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Pandemics</subject><subject>Plant Sciences</subject><subject>Platforms</subject><subject>Review</subject><subject>Reviews</subject><subject>risk</subject><subject>systematic review</subject><subject>Vaccines</subject><subject>Vectors (Biology)</subject><subject>Work platforms</subject><subject>Zoology</subject><issn>0973-7138</issn><issn>0250-5991</issn><issn>0973-7138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkc9Kw0AQh4MoWKsv4CngxUt0JpNsst5K_QuFXtTrstnsypY2qbtJpW_js_hkrkZQPOhhmDl8vx8MXxQdI5whQHHuMQUqE0gpAaA8T3AnGgEvKCmQyt0f93504P0CAHlGMIpmk6azVVtv48522vm4NbFtaruxdS-XPt5IpWwjO13HpnVvr9P5491lgvwinsR-6zu9kp1VsdMbq18Ooz0TQvroa4-jh-ur--ltMpvf3E0ns0QRsS6RyEBDhsh5wUpmsiJVqiINKNNMFQVnhocfJOUZ00jMaKxMlQMzwGRNjMbR6dC7du1zr30nVtYrvVzKRre9F4Q5pQAc-b9oWjJkWU5AAT35hS7a3jXhkUDlnPM0TKDSgVKu9d5pI9bOrqTbCgTx4UIMLkRwIT5dCAwhGkI-wM2Tdt_Vf6TeATXmifg</recordid><startdate>20230902</startdate><enddate>20230902</enddate><creator>Domado, Aminoddin M</creator><creator>Adaza, Homobono Jacob F</creator><creator>Beltran, Andrea Pauline Nicole C</creator><creator>Buenviaje, Leila M</creator><creator>Co, Catherine D</creator><creator>Combalicer, Leira R</creator><creator>Corona, Shiela May A</creator><creator>Cruz, John Benedict F</creator><creator>Dinjotian, Maria Adrianne Camille G</creator><creator>Esperanzate, Eli Marie S</creator><creator>Luna, Shaira Reinalyn G</creator><creator>Pascua, Ethelbert Justine R</creator><creator>Vicencio, Richard Rupert T</creator><creator>Reyes, Sherwin N</creator><general>Springer India</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>F1W</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H99</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L.F</scope><scope>L.G</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0002-0435-7731</orcidid></search><sort><creationdate>20230902</creationdate><title>Antibody titers of individuals vaccinated for COVID-19: A systematic review</title><author>Domado, Aminoddin M ; Adaza, Homobono Jacob F ; Beltran, Andrea Pauline Nicole C ; Buenviaje, Leila M ; Co, Catherine D ; Combalicer, Leira R ; Corona, Shiela May A ; Cruz, John Benedict F ; Dinjotian, Maria Adrianne Camille G ; Esperanzate, Eli Marie S ; Luna, Shaira Reinalyn G ; Pascua, Ethelbert Justine R ; Vicencio, Richard Rupert T ; Reyes, Sherwin N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-a160e0411997686f472ccb3e01a24c7796f9355a3546e136fe1bfb506f06ad363</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Bias</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cell Biology</topic><topic>COVID-19</topic><topic>COVID-19 infection</topic><topic>COVID-19 vaccines</topic><topic>Deactivation</topic><topic>Disease control</topic><topic>Homology</topic><topic>Immunogenicity</topic><topic>Life Sciences</topic><topic>messenger RNA</topic><topic>Microbiology</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Pandemics</topic><topic>Plant Sciences</topic><topic>Platforms</topic><topic>Review</topic><topic>Reviews</topic><topic>risk</topic><topic>systematic review</topic><topic>Vaccines</topic><topic>Vectors (Biology)</topic><topic>Work platforms</topic><topic>Zoology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Domado, Aminoddin M</creatorcontrib><creatorcontrib>Adaza, Homobono Jacob F</creatorcontrib><creatorcontrib>Beltran, Andrea Pauline Nicole C</creatorcontrib><creatorcontrib>Buenviaje, Leila M</creatorcontrib><creatorcontrib>Co, Catherine D</creatorcontrib><creatorcontrib>Combalicer, Leira R</creatorcontrib><creatorcontrib>Corona, Shiela May A</creatorcontrib><creatorcontrib>Cruz, John Benedict F</creatorcontrib><creatorcontrib>Dinjotian, Maria Adrianne Camille G</creatorcontrib><creatorcontrib>Esperanzate, Eli Marie S</creatorcontrib><creatorcontrib>Luna, Shaira Reinalyn G</creatorcontrib><creatorcontrib>Pascua, Ethelbert Justine R</creatorcontrib><creatorcontrib>Vicencio, Richard Rupert T</creatorcontrib><creatorcontrib>Reyes, Sherwin N</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ASFA: Marine Biotechnology Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Marine Biotechnology Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Journal of biosciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Domado, Aminoddin M</au><au>Adaza, Homobono Jacob F</au><au>Beltran, Andrea Pauline Nicole C</au><au>Buenviaje, Leila M</au><au>Co, Catherine D</au><au>Combalicer, Leira R</au><au>Corona, Shiela May A</au><au>Cruz, John Benedict F</au><au>Dinjotian, Maria Adrianne Camille G</au><au>Esperanzate, Eli Marie S</au><au>Luna, Shaira Reinalyn G</au><au>Pascua, Ethelbert Justine R</au><au>Vicencio, Richard Rupert T</au><au>Reyes, Sherwin N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody titers of individuals vaccinated for COVID-19: A systematic review</atitle><jtitle>Journal of biosciences</jtitle><stitle>J Biosci</stitle><date>2023-09-02</date><risdate>2023</risdate><volume>48</volume><issue>3</issue><spage>32</spage><epage>32</epage><pages>32-32</pages><artnum>32</artnum><issn>0973-7138</issn><issn>0250-5991</issn><eissn>0973-7138</eissn><abstract>An important preventive measure to mitigate the COVID-19 pandemic is vaccine implementation. In creating vaccines, evoking neutralizing antibody (NAb) production is the main objective. This review determines and compares the NAb titers produced by COVID-19 vaccine recipients based on the vaccine type and the manner of administration. This review includes published articles on studies with healthy participants with a minimum age of 18 years, without previous infections, and those who were given Emergency Use License (EUL) vaccines from WHO. Bias assessment was performed using the Cochrane Risk of Bias and the Newcastle–Ottawa Scale. In all the studies, 40.82% of the primary doses were viral vector platforms. For booster doses, 50% were mRNA platforms. Messenger RNA (mRNA) vaccines have higher titers as homologous than as heterologous vaccines. However, inactivated vaccines and viral vector vaccines have lower titers as homologous than as heterologous vaccines. Meanwhile, subunit vaccines lack data for their titers. Based on the antibody titers, homologous mRNA vaccines are more viral-protective than their heterologous counterparts. Heterologous inactivated and viral vector vaccines are more protective than homologous combinations, mainly when mRNA is the other type in those heterologous combinations. This is because mRNA vaccines elicit higher immunogenicity compared to other types.</abstract><cop>New Delhi</cop><pub>Springer India</pub><doi>10.1007/s12038-023-00355-1</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-0435-7731</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0973-7138 |
| ispartof | Journal of biosciences, 2023-09, Vol.48 (3), p.32-32, Article 32 |
| issn | 0973-7138 0250-5991 0973-7138 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3153200919 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Indian Academy of Sciences; SpringerLink Journals - AutoHoldings |
| subjects | Antibodies Bias Biomedical and Life Sciences Biomedicine Cell Biology COVID-19 COVID-19 infection COVID-19 vaccines Deactivation Disease control Homology Immunogenicity Life Sciences messenger RNA Microbiology mRNA mRNA vaccines Pandemics Plant Sciences Platforms Review Reviews risk systematic review Vaccines Vectors (Biology) Work platforms Zoology |
| title | Antibody titers of individuals vaccinated for COVID-19: A systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T02%3A06%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20titers%20of%20individuals%20vaccinated%20for%C2%A0COVID-19:%20A%20systematic%20review&rft.jtitle=Journal%20of%20biosciences&rft.au=Domado,%20Aminoddin%20M&rft.date=2023-09-02&rft.volume=48&rft.issue=3&rft.spage=32&rft.epage=32&rft.pages=32-32&rft.artnum=32&rft.issn=0973-7138&rft.eissn=0973-7138&rft_id=info:doi/10.1007/s12038-023-00355-1&rft_dat=%3Cproquest_cross%3E2859992999%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2859992999&rft_id=info:pmid/&rfr_iscdi=true |